Boehringer Ingelheim on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals use contract pharmacies.

Boehringer Ingelheim Halts 340B Pricing on Contract Pharmacy Drugs

Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.

BI this morning confirmed that it has begun denying 340B pricing to hospitals on bill to/ship to orders involving contract pharmacies. BI told covered entities on June 31 that it would take the step on Aug. 1.

Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.  

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer